FischlMARichmanDDGriecoMHGottliebMSVolberdingPALaskinOL. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N Engl J Med1987; 317: 185–91.
2.
RichmanDDFischlMAGriecoMHGottliebMSVolberdingPALaskinOL. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N Engl J Med1987; 317: 192–7.
3.
DournonERozenbaumWMichonCPerronneCDeTruchisPBouvetE. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet1988; 2: 1297–302.
4.
FischlMARichmanDDCauseyDMGriecoMHBrysonYMidvanD. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA1989; 262: 2405–10.
5.
FischlMARichmanDDHansenNCollierACCareyJTParaMF. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: A double-blind, placebo-controlled trial. Ann Intern Med1990; 112: 727–37.
6.
VolberdingPALagakosSWKochMAPettinelliCMyersMWBoothDK. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med1990; 322: 941–9.
7.
FischlMAParkerCBPettinelliCWulfsohnMHirschMSCollierAC. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med1990; 323: 1009–14.
8.
CollierACBozzetteSCoombsRWCauseyDMSchoenfeldDASpectorSA. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med1990; 323: 1015–21.
9.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. JAMA1984; 251: 351–74.
10.
FrickMHEloOHaapaKHeinonenOPHeinsalmiPHeloP. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med1987; 317: 1237–45.
MuldoonMFManuckSBMatthewsKA. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. Br Med J1990; 301: 309–14.
13.
VirkkunenM. Serum cholesterol in antisocial personality. Neuropsychobiology1979; 5: 27–30.
14.
VirkkunenMPenttinenH. Serum cholesterol in aggressive conduct disorder: A preliminary study. Biol Psychiatry1983; 19: 435–9.
15.
KaplanJRManuckSB. The effects of fat and cholesterol on aggressive behavior in monkeys. Psychosom Med1990; 52: 222–7.
16.
CoccaroEF. Central serotonin and impulsive aggression. Br J Psychiatry1989; 155 (suppl 8):52–62.
17.
YehudaSLeprohon-GreenwoodCEDixonLMCoscinaDV. Effects of dietary fat on pain threshold, thermoregulation and motor activity in rats. Pharmacol Biochem Behav1986; 24: 1775–7.
18.
KapoorWN. Diagnostic evaluation of syncope. Am J Med1991; 90: 91–106.
ManolisASLinzerMSalemDEstesNAM. Syncope: Current diagnostic evaluation and management. Ann Intern Med1990; 112: 850–63.
21.
LinzerM. Syncope: 1991. Am J Med1991; 90: 1–5.
22.
AlmquistAGoldenbergIFMilsteinSChenMYChenXHansenR. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med1989; 320: 346–51.
23.
MilsteinSBuetikoferJDunniganABendittDGGornickCReyesWJ. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol1990; 65: 1339–44.
24.
GrubbBPTemsey-ArmosPHahnHElliotL. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med1991; 90: 6–10.
25.
RavieleAGasparaniGDiPedeFDelisePBonsoAPiccoloE. Usefulness of head-up tilt test in evaluating patients with syncope of unknown origin and negative electrophysiologic study. Am J Cardiol1990; 65: 1322–7.
26.
ThileniusOGQuinonesJAHusayniTSNovakJ. Tilt test for diagnosis of unexplained syncope in pediatric patients. Pediatrics1991; 87: 334–8.
27.
Abi-SamraFMaloneyJDFouad-TaraziFMCastleLW. The usefulness of head-up tilt testing and hemodynamic investigations in the workup of syncope of unknown origin. PACE1988; 11: 1202–14.
28.
WaxmanMBYaoLCameronDAWaldRWRosemanJ. Isoproterenol induction of vasodepressor-type reaction in vasodepressor-prone persons. Am J Cardiol1989; 63: 58–65.
29.
KennyRAIngramABaylissJSuttonR. Head-up tilt: A useful test for investigating unexplained syncope. Lancet1986; 1: 1352–5.
30.
McLaranCJGershBJOsbornMJWoodDLSugrueDDHolmesDR. Increased vagal tone as an isolated finding in patients undergoing electrophysiological testing for recurrent syncope: Response to long term anticholinergic agents. Br Heart J1986; 55: 53–7.
31.
GoldenbergIFAlmquistADunbarDNMilsteinSProtzkerMRBendittDG. Prevention of neurally-mediated syncope by selective beta-1 adrenoceptor blockade (abstract). Circulation1987; 77 (suppl IV):IV–133.
32.
WyheGVMcKinnieJAvitallBGilbertCKershenovichSSraJ. Unexplained discordance between acute intravenous and long term oral beta blockade for control of neurocardiogenic dysfunction diagnosed during head up tilt testing (abstract). Circulation1989; 80 (suppl II):II–656.
33.
AssoAMilsteinSDunniganARemoleSBendittDG. Prognostic significance of parenteral metoprolol during head-up tilt-table testing: Follow-up after 3 years (abstract). Circulation1991; 84 (suppl II):II–409.
